Scribe Therapeutics (SCTX) news
Recent news
Scribe Therapeutics Inc.: H.C. Wainwright initiates coverage with buy rating and target price $60
AInvest Wire · 8h agoScribe Therapeutics Inc: Leerink Partners initiates coverage with outperform rating; price target $37
Leerink Partners has initiated coverage of Scribe Therapeutics Inc. (Nasdaq: SCTX) with an "outperform" rating and a price target of $37 per share. The firm's decision follows the company's successful initial public offering (IPO), which closed on July 27, 2026, with the issuance of 9,867,000…
AInvest Wire · Aug 18, 2026Scribe Therapeutics upsized IPO prices at $15/shr
Scribe Therapeutics has priced its initial public offering (IPO) at $15 per share, above the initial $13–$15 range, raising $107.25 million from the sale of 7.15 million shares. The company also has a $10.5 million overallotment option, which, if exercised, would bring total proceeds to…
AInvest Wire · Jul 24, 2026Scribe Therapeutics said to guide IPO pricing to top of range
AInvest Wire · Jul 23, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.